Managers / Q4 2025 · view latest →
Foresite Capital Management VI LLC
CIK 0002013341 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management Vi LLC reported $331M in U.S.-listed holdings across 12 positions for Q4 2025.
The portfolio is heavily concentrated: CGON alone accounts for 27.9% of reported value.
Compared with Q3 2025, the fund opened 3 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 86.3% · $285M
- ADR · 10.3% · $34M
- Other · 3.4% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NTRANatera, Inc. | NEW | +67.4K | 67.4K | +$15M | $15M |
| AGIOAGIOS PHARMACEUTICALS, INC. | NEW | +530.0K | 530.0K | +$14M | $14M |
| Atai Beckley N.V. | NEW | +2.75M | 2.75M | +$11M | $11M |
| AKROAkero Therapeutics, Inc. | SOLD OUT | −244.9K | 0 | −$12M | $0 |
| RNAGBPAvidity Biosciences, Inc. | SOLD OUT | −40.0K | 0 | −$2M | $0 |
| CASI Pharmaceuticals, Inc. | SOLD OUT | −980.0K | 0 | −$2M | $0 |
| CRVSCorvus Pharmaceuticals, Inc. | TRIMMED | −350.0K | 1.38M | −$2M | $11M |
| VSTMVerastem, Inc. | ADDED | +520.0K | 3.14M | +$1M | $24M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc.history → | COM | 27.88% | $92M | 2.22M |
| 2 | RAPTRAPT Therapeutics, Inc.history → | COM | 16.00% | $53M | 1.56M |
| 3 | ALMSALUMIS INC.history → | COM | 12.53% | $41M | 4.25M |
| 4 | 260Centessa Pharmaceuticals plchistory → | SPONSORED ADS | 10.31% | $34M | 1.36M |
| 5 | VSTMVerastem, Inc.history → | COM | 7.32% | $24M | 3.14M |
| 6 | DNLIDenali Therapeutics Inc.history → | COM | 4.99% | $17M | 1.00M |
| 7 | NTRANatera, Inc.history → | COM | 4.66% | $15M | 67.4K |
| 8 | AGIOAGIOS PHARMACEUTICALS, INC.history → | COM | 4.36% | $14M | 530.0K |
| 9 | KYMRKymera Therapeutics, Inc.history → | COM | 3.44% | $11M | 146.3K |
| 10 | Atai Beckley N.V. | SHS | 3.40% | $11M | 2.75M |
| 11 | CRVSCorvus Pharmaceuticals, Inc.history → | COM | 3.21% | $11M | 1.38M |
| 12 | HNGEHinge Health, Inc.history → | CL A | 1.90% | $6M | 135.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $460M | 17 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $331M | 12 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $259M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $178M | 20 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $183M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $224M | 14 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.